Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-07-24
2007-07-24
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C514S002600, C514S008100, C514S012200, C514S885000
Reexamination Certificate
active
10379741
ABSTRACT:
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
REFERENCES:
patent: 5591630 (1997-01-01), Andersen et al.
patent: 5660824 (1997-08-01), Grabstein et al.
patent: 5795966 (1998-08-01), Grabstein et al.
patent: 6001973 (1999-12-01), Strom et al.
patent: 6083477 (2000-07-01), Goldenberg
patent: 6165466 (2000-12-01), Grabstein et al.
patent: 6184359 (2001-02-01), Grabstein et al.
patent: 6258352 (2001-07-01), Shimonaka
patent: 2002/0182178 (2002-12-01), Grooten et al.
patent: 1 273 304 (2003-01-01), None
patent: 1 273 304 (2003-01-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 00/02582 (2000-01-01), None
patent: WO 00/02582 (2000-01-01), None
patent: WO 01/02003 (2001-01-01), None
patent: WO 03/017935 (2003-03-01), None
Panka et al. Proc. Natl. Acad. Sci. USA vol. 85, pp. 3080-3084 (May 1988).
Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982).
Amit et al. Science, vol. 233, pp. 747-753, (Aug. 1986).
Beers & Berkow Editors, The Merck Manual (1999) 17thedition, pp. 165-177, pp. 986-995.
Bentley DL. Most kappa immunoglobulin mRNA in human lymphocytes is homologous to a small family of germ-line V genes. Nature. Jan. 5-11, 1984;307(5946):77-80.
Davies J, et al. Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding. Immunotechnology. Sep. 1996;2(3):169-79.
Kipps TJ, et al. Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med. Mar. 1, 1988;167(3):840-52.
Stausberg RL, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A. Dec. 24, 2002;99(26):16899-903.
Villadsen LS, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. Nov. 2003;112(10):1571-80.
Baadsgaard Ole
Gerritsen Arnout F.
Peterson Jørgen
Schuurman Janine
van de Winkel Jan G. J.
Genmab A/S
Lahive & Cockfield LLP
Mertz Prema
Remillard, Esq. Jane E.
LandOfFree
Methods of treating using anti-IL-15 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating using anti-IL-15 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating using anti-IL-15 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808052